Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pilaralisib (XL-147) 是一种有效的、选择性的 I 类PI3Ks 抑制剂,能够抑制 PI3Kα (IC50:39 nM),PI3Kβ (IC50:383 nM),PI3Kγ (IC50:23 nM) 和 PI3Kδ (IC50:36 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 266 | 现货 | ||
2 mg | ¥ 378 | 现货 | ||
5 mg | ¥ 619 | 现货 | ||
10 mg | ¥ 993 | 现货 | ||
25 mg | ¥ 1,670 | 现货 | ||
50 mg | ¥ 2,480 | 现货 | ||
100 mg | ¥ 3,980 | 现货 | ||
500 mg | ¥ 8,460 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 739 | 现货 |
产品描述 | Pilaralisib (XL-147) is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others. |
靶点活性 | PI3Kγ:23 nM, PI3Kα:39 nM, PI3Kβ:36 nM, PI3Kδ:36 nM |
体外活性 | Pilaralisib exhibits cytotoxic activity in Pediatric PreClinicalal Testing Program (PPTP) cell lines, with a median relative IC50 value of 10.9 mM (range 2.7 mM to 24.5 mM).[2] |
体内活性 | In BALB/c nu/nu mice, Pilaralisib (100 mg/kg, p.o.) induces tumor growth inhibition for solid glioma xenografts. Pilaralisib is well tolerated, with only 0.7% toxicity rate in the treated groups, similar to that observed for control animals.[2] In athymic female mouse, Pilaralisib (100 mg/kg, p.o.) significantly delays tumor growth without significant drug-related toxicity.[3] |
激酶实验 | In vitro kinase inhibition assays: Kinase activity for PI3K isoforms is measured as the percentage of ATP consumed following the kinase reaction using luciferase–luciferin-coupled chemiluminescence, with ATP concentrations approximately equal to the Km for each respective kinase. Kinase reactions are initiated by combining test compounds, ATP and kinase in a 20 μL volume. PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ final enzyme concentrations are 0.5, 8, 20, and 2 nM, respectively. Of note, 0.5 μL dimethyl sulfoxide (DMSO) containing varying concentrations of the test compound is mixed with 10 μL enzyme solution (2×concentration). Kinase reactions are initiated by the addition of 10 μL of liver phosphatidylinositol and ATP solution (2×concentration). Assay concentrations for VPS34, ATP, and phosphatidylinositol are 40 nM, 1 μM, and 5 μM, respectively |
细胞实验 | Cell proliferation is measured by using MTT or pre-mixed WST-1 reagent. For MTT/WST-1 assays, 10,000 cells/well are seeded in 96-well plates. 24 h after plating, cells are treated with DMSO or pilaralisib. After 5 days of treatment, MTT/WST-1 assays are performed.(Only for Reference) |
别名 | SAR245408, XL-147 |
分子量 | 541.02 |
分子式 | C25H25ClN6O4S |
CAS No. | 934526-89-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (171.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8484 mL | 9.2418 mL | 18.4836 mL | 46.209 mL |
5 mM | 0.3697 mL | 1.8484 mL | 3.6967 mL | 9.2418 mL | |
10 mM | 0.1848 mL | 0.9242 mL | 1.8484 mL | 4.6209 mL | |
20 mM | 0.0924 mL | 0.4621 mL | 0.9242 mL | 2.3105 mL | |
50 mM | 0.037 mL | 0.1848 mL | 0.3697 mL | 0.9242 mL | |
100 mM | 0.0185 mL | 0.0924 mL | 0.1848 mL | 0.4621 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pilaralisib 934526-89-3 PI3K/Akt/mTOR signaling PI3K inhibit XL147 Phosphoinositide 3-kinase Inhibitor SAR245408 SAR-245408 SAR 245408 XL 147 XL-147 inhibitor